Subcutaneous Immunoglobulin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Application (Primary Immunodeficiency Diseases, Secondary Immunodeficiency Diseases, Others), by End-User and by Geography.

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 13.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The subcutaneous immunoglobulin  market studied was projected to grow with a CAGR of nearly 13.3% over the forecast period. The major factors attributing to the growth of the market include increasing use of subcutaneous immunoglobulin for primary immunodefeciency disorders, increasing geriatric population and patient pool. The growing demand of the subcutaneous immunoglobulin infusions are due to the advantages like absence of necessity of vascular access, easy use at home, more stable serum IgG levels and efficient prevention against infections. Furthermore the growing investements in research and development programs by the biotechnology and pharmaceutical companiesis boosting the market growth. Rising  government fundings and increasing awareness about usage of subcutaneous immunoglobulin for treatment of immunodefeciency disorders boosts the market growth. However the stringent government regulations and high risk of the side effects of the treatment are the major drawbacks for the market growth.

Scope of the Report

As per the scope of the report, subcutaneous immunoglobulin infusions are given by gradually injecting purified immunoglobulin into the fatty tissue just beneath the skin. This report is segmented by Application, by End-User, and by Geography.

By Application
Primary Immunodeficiency Diseases
Secondary Immunodeficiency Diseases
By End-User
Homecare Settings
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Primary Immunodeficiency Diseases Segment to Dominate the Market in the Forecast Period

  • Primary immunodeficiency diseases have the largest market share and are expected to do the same in the forecast period. The dominance of the segment can be credited to the soaring prevalence of primary immunodeficiency diseases, growing usage and awareness of subcutaneous immunoglobulin, rising research and development activities in the field of plasma-derived therapeutics.
  • According to the Immune Deficiency Foundation, there are approximately 250,000 people who have been diagnosed with primary immunodeficiency diseases in the United States. The rate of incidence of the severe combined immunodeficiency disease was 1 in 10,000 in 2008 and it has changed to 1 in 4000, in 2018. The prevalence of primary immunodeficiency diseases is rising and hence the market growth.
Antithrombin Market

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall subcutaneous immunoglobulin market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of primary immunodeficiency diseases patients and increasing geriatric population in the region, established healthcare infrastructure, are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Antithrombin Market

Competitive Landscape

The subcutaneous immunoglobulin market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Takeda Pharmaceutical Company Limited, Biotest AG, CSL Behring, Grifols, S.A., Octapharma AG, Kedrion S.p.A., Bio Products laboratory.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing use of subcutaneous immunoglobulin for primary immunodefeciency disorders

      2. 4.2.2 Increasing geriatric population and patient pool

      3. 4.2.3 Rise in government funding

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent government regulations

      2. 4.3.2 High risk of side effects

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Application

      1. 5.1.1 Primary Immunodeficiency Diseases

      2. 5.1.2 Secondary Immunodeficiency Diseases

      3. 5.1.3 Others

    2. 5.2 By End-User

      1. 5.2.1 Hospitals

      2. 5.2.2 Homecare Settings

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Takeda Pharmaceutical Company Limited

      2. 6.1.2 Biotest AG

      3. 6.1.3 CSL Behring

      4. 6.1.4 Grifols, S.A.

      5. 6.1.5 Octapharma AG

      6. 6.1.6 Kedrion S.p.A.

      7. 6.1.7 Bio Products laboratory

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Subcutaneous Immunoglobulin Market market is studied from 2018 - 2026.

The Subcutaneous Immunoglobulin Market is growing at a CAGR of 13.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Takeda Pharmaceutical Company Limited, Biotest AG, CSL Behring, Grifols, S.A., Octapharma AG are the major companies operating in Subcutaneous Immunoglobulin Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!